ADAPTIMMUNE THERAPEUTICS PLC (ADAPY) Return on equity 2015–2024
ADAPTIMMUNE THERAPEUTICS PLC (ADAPY) return on equity by fiscal year — reported net income divided by year-end shareholders’ equity.
-597.6%FY2024 · since FY2015: -8.5% → -597.6%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2024 | -597.6% | -309.5 pp |
| FY2023 | -288.2% | -86.1 pp |
| FY2022 | -202.1% | -125.3 pp |
| FY2021 | -76.8% | -38.6 pp |
| FY2020 | -38.1% | +72.8 pp |
| FY2019 | -110.9% | -72.3 pp |
| FY2018 | -38.7% | -4.1 pp |
| FY2017 | -34.6% | +8.5 pp |
| FY2016 | -43.1% | -34.6 pp |
| FY2015 | -8.5% | — |
ROE = reported net income ÷ reported year-end shareholders’ equity for the same fiscal year. Heavy buybacks shrink equity and can push ROE very high (or negative-equity years drop out).
Source: SEC XBRL filings · For reference only · Not investment advice